Medpace Holdings Inc (NASDAQ:MEDP) Major Shareholder Sells $3,648,749.40 in Stock

Medpace Holdings Inc (NASDAQ:MEDP) major shareholder Medpace Investors, Llc sold 34,380 shares of the company’s stock in a transaction dated Friday, July 24th. The shares were sold at an average price of $106.13, for a total value of $3,648,749.40. Following the completion of the sale, the insider now owns 7,605,456 shares of the company’s stock, valued at approximately $807,167,045.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Medpace Investors, Llc also recently made the following trade(s):

  • On Tuesday, July 28th, Medpace Investors, Llc sold 214,499 shares of Medpace stock. The stock was sold at an average price of $127.23, for a total value of $27,290,707.77.
  • On Wednesday, July 22nd, Medpace Investors, Llc sold 63,968 shares of Medpace stock. The stock was sold at an average price of $108.58, for a total value of $6,945,645.44.
  • On Monday, July 20th, Medpace Investors, Llc sold 37,044 shares of Medpace stock. The stock was sold at an average price of $105.39, for a total value of $3,904,067.16.
  • On Thursday, July 16th, Medpace Investors, Llc sold 15,273 shares of Medpace stock. The stock was sold at an average price of $103.70, for a total value of $1,583,810.10.
  • On Monday, July 13th, Medpace Investors, Llc sold 6,127 shares of Medpace stock. The stock was sold at an average price of $100.50, for a total value of $615,763.50.
  • On Thursday, July 9th, Medpace Investors, Llc sold 2,455 shares of Medpace stock. The stock was sold at an average price of $100.15, for a total value of $245,868.25.

MEDP stock opened at $124.76 on Thursday. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.89 and a quick ratio of 0.89. The stock has a market capitalization of $4.41 billion, a P/E ratio of 44.40 and a beta of 1.22. The business has a 50-day moving average of $95.59 and a 200-day moving average of $88.37. Medpace Holdings Inc has a fifty-two week low of $58.72 and a fifty-two week high of $144.49.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, July 27th. The company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.40 by $0.28. Medpace had a return on equity of 16.20% and a net margin of 12.11%. The firm had revenue of $205.00 million during the quarter, compared to analysts’ expectations of $181.17 million. During the same period in the prior year, the firm posted $0.81 earnings per share. The business’s quarterly revenue was down 4.3% compared to the same quarter last year. Equities analysts expect that Medpace Holdings Inc will post 2.36 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its position in Medpace by 5.5% during the first quarter. Geode Capital Management LLC now owns 450,923 shares of the company’s stock valued at $33,088,000 after purchasing an additional 23,691 shares during the last quarter. AXA acquired a new position in Medpace during the first quarter valued at approximately $1,123,000. Norges Bank acquired a new position in Medpace during the fourth quarter valued at approximately $33,391,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Medpace by 33.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,474 shares of the company’s stock valued at $182,000 after purchasing an additional 626 shares during the last quarter. Finally, First Trust Advisors LP boosted its position in Medpace by 6.0% during the first quarter. First Trust Advisors LP now owns 114,321 shares of the company’s stock valued at $8,389,000 after purchasing an additional 6,503 shares during the last quarter. 79.83% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have issued reports on the company. SunTrust Banks increased their price target on Medpace from $95.00 to $124.00 and gave the stock a “hold” rating in a report on Wednesday. Zacks Investment Research upgraded Medpace from a “sell” rating to a “hold” rating in a report on Wednesday, May 20th. Wolfe Research cut Medpace from an “outperform” rating to a “peer perform” rating and set a $91.00 price objective for the company. in a research report on Wednesday, May 13th. BidaskClub raised Medpace from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Finally, Credit Suisse Group upped their price objective on Medpace from $92.00 to $114.00 and gave the stock an “outperform” rating in a research report on Tuesday. Five analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $99.86.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

See Also: What is insider trading?

Insider Buying and Selling by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.